Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination

Shunsuke Ogata; Yoshito Ishi; Keiichiro Asano; Erena Kobayashi; Shun Kubota; Keita Takahashi; Yosuke Miyaji; Yuichi Higashiyama; Hideto Joki; Hiroshi Doi; Michiaki Koga; Hideyuki Takeuchi; Fumiaki Tanaka

doi:10.2169/internalmedicine.8967-21

This article has now been updated. Please use the final version.

Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination

Shunsuke Ogata, Yoshito Ishi, Keiichiro Asano, Erena Kobayashi, Shun Kubota, Keita Takahashi, Yosuke Miyaji, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Michiaki Koga, Hideyuki Takeuchi, Fumiaki Tanaka

Author information

Shunsuke Ogata
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Yoshito Ishi
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Keiichiro Asano
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Erena Kobayashi
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Shun Kubota
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Keita Takahashi
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Yosuke Miyaji
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Yuichi Higashiyama
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Hideto Joki
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Hiroshi Doi
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Michiaki Koga
Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan
Hideyuki Takeuchi
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan
Fumiaki Tanaka
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan

Keywords: vaccination, COVID-19, Guillain-Barré syndrome, sensory ataxia, dysgeusia

JOURNAL OPEN ACCESS Advance online publication

Article ID: 8967-21

DOI https://doi.org/10.2169/internalmedicine.8967-21

The final version of this article is now available: Vol. 61 (2022), No. 11 pp. 1757-1760

Details

Abstract

Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.

Corresponding author

Register with J-STAGE for free!